Groundbreaking Research at Baylor University Medical Center

In a groundbreaking initiative, Baylor University Medical Center in Dallas has launched a pioneering breast cancer research study. This clinical trial, called TRIM-EBC, is the first to investigate how the latest weight loss drugs, known as GIP/GLP-1 receptor agonists, may help prevent breast cancer recurrence in patients who are overweight or obese.

Bigger Stakes for Thousands of Women

Backed by generous donations and partnerships with Eli Lilly and Haystack Oncology, this crucial study aims to determine if weight loss achieved with Zepbound® (tirzepatide) can reduce circulating tumor DNA (ctDNA) in patients, a key indicator of breast cancer recurrence risk.

Leading Experts on a Mission

Co-principal investigators Dr. Joyce Ann O'Shaughnessy and Dr. Ronan Kelly are at the helm of this exciting research. Dr. O'Shaughnessy emphasizes the potential impact of these findings, highlighting that breakthroughs in this area could pave the way for improved treatment for the thousands of Texas patients battling breast cancer annually, and even beyond.

Understanding the Risks of Obesity in Breast Cancer

Research consistently identifies a troubling trend: individuals diagnosed with early-stage breast cancer who are ctDNA positive face a significantly heightened risk of recurrence. Furthermore, obesity and excess weight have been linked to more aggressive forms of breast cancer and worse outcomes. Surprisingly, nearly two-thirds of women reported gaining an average of 20 pounds post-diagnosis, with 17% gaining over 44 pounds.

The Science Behind Weight and Health

Experts suggest that chronic inflammation and increased levels of estrogen and insulin contribute to this connection between obesity and cancer. Compelling data suggests that significant weight loss might reduce cancer risk, as shown in bariatric surgery studies linking sustained weight loss to lower breast cancer rates.

What You Need to Know About Zepbound®

Zepbound is an innovative prescription injectable that utilizes tirzepatide to help individuals with obesity lose weight effectively. While these medications offer hope, current health guidelines still champion the importance of diet and exercise as the cornerstone for reducing breast cancer recurrence risk.

A Commitment to Fighting Cancer Recurrence

Dr. Kelly states that this research contributes to Baylor Scott & White's broader strategy within the National Cancer Plan, aiming to drastically reduce cancer mortality rates. The TRIM-EBC trial forms a crucial part of the Texas Cancer Interception Institute's mission to explore innovative solutions.

Stay Informed

For more insights on this groundbreaking study, visit BSWHealth.com/TrimStudy.